FDA approves Ozempic to reduce risks from chronic kidney disease in diabetes patients
FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
FDA approves Ozempic to help reduce risk of worsening chronic kidney disease
The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of
US FDA approves Novo Nordisk's Ozempic to cut risk of diabetic kidney disease progression
The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with chronic kidney disease (CKD),
Novo Nordisk’s Ozempic Gets FDA Approval as Kidney-Disease Treatment
Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type 2 diabetes and chronic kidney disease, Novo Nordisk said.
Verywell Health on MSN18h
Doctors Can Now Prescribe Ozempic to Reduce Kidney Disease Risks in Diabetes Patients
The FDA has approved popular antiobesity drug Ozempic to help protect patients with type 2 diabetes from kidney disease.
Pharm Exec1d
FDA Approves Novo Nordisk’s Ozempic to Reduce Kidney Disease in Patients with Type 2 Diabetes, Chronic Kidney Disease
Approval was based on results from the Phase IIIb FLOW trial, which demonstrated a 24% relative risk reduction in kidney disease, kidney failure, and cardiovascular death in patients treated with Ozempic.
Managed Healthcare Executive2d
FDA Approves Ozempic to Reduce Kidney Disease in Type 2 Diabetes
Chronic kidney disease affects about 37 million adults in the United States and is expected to rise. It is a common complication of type 2 diabetes.
960 The Ref on MSN1d
FDA approves Ozempic to reduce risk of kidney disease progression, cardiovascular death
The Food and Drug Administration approved Ozempic to be used to lessen the risk of kidney disease from getting worse, end-stage kidney disease and cardiovascular disease-caused death for patients with type 2 diabetes and chronic kidney disease.
McKnight's Long-Term Care News1d
FDA expands Ozempic to treat kidney disease in people with diabetes
The US Food and Drug Administration on Tuesday approved Ozempic for adults with type 2 diabetes and chronic kidney disease (CKD). The drug is now indicated specifically to treat kidney failure, prevent death from cardiovascular disease,
FDA OK's Ozempic To Protect Kidneys in Type 2 Diabetes Patients
Type 2 diabetes is a leading cause of chronic kidney disease, which affects more than 1 in 7 U.S. adults. The new approval allows doctors to prescribe Ozempic specifically to lower the risk of kidney failure, dialysis and death from heart-related problems in these high-risk patients.
FDA approves new type of nonopioid painkiller for acute pain
The drug, Journavx, from Vertex Pharmaceuticals, reduced pain after surgery in clinical trials. Experts hope it can lead to fewer opioid prescriptions.
Seeking Alpha3h
2025 Will Be A Major Year For ProKidney's Rilparencel In CKD Treatment
Currently, Rilparencel’s Phase 3 is planned to deliver full data by Q3 2027 if no surrogate endpoint is found that’s suitable for the FDA. The FDA confirmed in ... 2 diabetes [T2DM] patients at risk of kidney failure. Nonetheless, I do believe it ...
Frontiers4h
Modifiable Risk Factors for Chronic Kidney Disease Progression
Chronic kidney disease (CKD) is a growing global health concern, significantly contributing to morbidity and mortality rates worldwide. Characterized by a